Hope Tribune

RNA Interference Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

RNA Interference Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

October 31
20:12 2023
RNA Interference Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “RNA Interference Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the RNA Interference Pipeline Report

  • DelveInsight’s RNA Interference pipeline report depicts a robust space with 20+ active players working to develop 90+ pipeline therapies for RNA Interference treatment.
  • The leading companies working in the RNA Interference Market include Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Amgen, Sirnaomics, Silence Therapeutics, Phio Pharmaceuticals, Medesis Pharma, Atalanta Therapeutics, Mirimus/ Biogen, Mallinckrodt/Silence Therapeutics, and others.
  • Promising RNA Interference Pipeline Therapies in the various stages of development include siG12D LODER, Inclisiran, Bevasiranib, and others.
  • September 2023: University of Oxford announced a study of Phase 3 clinical trials for Inclisiran. The study is intended to be conducted at approximately 180 clinical sites in the UK and the USA. Approximately 15,000 participants aged 40 years or older for men, and 55 years or older for women, with pre-existing atherosclerotic cardiovascular disease will be randomized between inclisiran sodium 300 mg and matching placebo (given by subcutaneous injection on the day of randomization, at 3 months and then every 6-months) in a 1:1 ratio for a planned median duration of about 5 years.

 

Request a sample and discover the recent advances in RNA Interference Treatment Drugs @ RNA Interference Pipeline Report

 

In the RNA Interference pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, RNA Interference clinical trials, NDA approvals (if any), and product development activities comprising the technology, RNA Interference collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

RNA Interference Overview

RNA interference (RNAi) is one of the pathways, collectively named RNA silencing pathways that employ small RNAs as guides for sequence-specific silencing. RNAi was discovered in C. elegans and defined as sequence-specific mRNA degradation induced by long double-stranded RNA (dsRNA). The RNA interference (RNAi) pathway regulates mRNA stability and translation in nearly all human cells.

 

Find out more about RNA Interference Therapeutics Assessment @ RNA Interference Preclinical and Discovery Stage Products

 

RNA Interference Emerging Drugs Profile

  • Vutrisiran: Alnylam Pharmaceuticals
  • Cemdisiran: Alnylam Pharmaceuticals
  • SR061: Suzhou Ribo Life Science
  • ARO-APOC3: Arrowhead Pharmaceuticals
  • DCR-PHXC: Dicerna Pharmaceuticals

 

RNA Interference Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing RNA Interference therapies. The RNA Interference companies which have their RNA Interference drug candidates in the most advanced stage, i.e. Pre-Registration include Alnylam Pharmaceuticals.

 

DelveInsight’s RNA Interference pipeline report covers around 90+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

RNA Interference pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

RNA Interference Pipeline Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging RNA Interference Pipeline Therapies @ RNA Interference Clinical Trials Assessment

 

Scope of the RNA Interference Pipeline Report

  • Coverage- Global
  • RNA Interference Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • RNA Interference Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • RNA Interference Companies- Alnylam Pharmaceuticals, Suzhou Ribo Life Science, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Sylentis, Vir Biotechnology, Arbutus Biopharma, Silenseed, OliX Pharmaceuticals, Bio-Path Holdings, Janssen Pharmaceuticals, Eli Lilly and Company, Amgen, Sirnaomics, Silence Therapeutics, Phio Pharmaceuticals, Medesis Pharma, Atalanta Therapeutics, Mirimus/ Biogen, Mallinckrodt/Silence Therapeutics, and others.
  • RNA Interference Pipeline Therapies- siG12D LODER, Inclisiran, Bevasiranib, and others.

 

Dive deep into rich insights for new drugs for RNA Interference Treatment, Visit @ RNA Interference Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. RNA Interference: Overview
  4. Pipeline Therapeutics
  5. RNA Interference Therapeutic Assessment
  6. RNA Interference– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Vutrisiran: Alnylam Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Last Stage Products (Phase III)
  11. Cemdisiran: Alnylam Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug Name : Company Name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. RNA Interference Key Companies
  21. RNA Interference Key Products
  22. RNA Interference- Unmet Needs
  23. RNA Interference Market Drivers
  24. RNA Interference Barriers
  25. RNA Interference Future Perspectives and Conclusion
  26. RNA Interference Analyst Views
  27. RNA Interference Key Companies
  28. Appendix

 

For further information on the RNA Interference Pipeline therapeutics, reach out to RNA Interference Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting

Categories